Greenwich LifeSciences, Inc.

Name: Greenwich LifeSciences, Inc. standardized financial statements, quarterly
Creator: Listed

GLSINasdaqCIK 1799788HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$4.0m, Q2 FY2026

Net income−$3.9m, Q2 FY2026

Greenwich LifeSciences, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Research and development	$k	2,158	2,333	2,195	2,308	2,292	8,686	2,271	3,416	3,267	8,266	5,208	3,559
Operating income	$k	(2,503)	(2,836)	(2,537)	(2,661)	(2,729)	(9,710)	(2,769)	(3,769)	(4,175)	(7,945)	(5,726)	(4,022)
Net income	$k	(2,392)	(2,747)	(2,473)	(2,607)	(2,669)	(9,666)	(2,745)	(3,749)	(3,711)	(9,154)	(5,657)	(3,949)
Diluted EPS	$ per share	(0.19)	not reported	(0.19)	(0.20)	(0.20)	not reported	(0.21)	(0.28)	(0.27)	not reported	(0.39)	(0.27)
Basic EPS	$ per share	(0.19)	not reported	(0.19)	(0.20)	(0.20)	not reported	(0.21)	(0.28)	(0.27)	not reported	(0.39)	(0.27)

Balance sheet

Cash and equivalents$8.9m, Q2 FY2026

Shareholders' equity$3.1m, Q2 FY2026

Greenwich LifeSciences, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	9.1	7.0	5.5	7.2	5.8	4.1	2.7	3.1	3.8	6.2	10.5	8.9
Current assets	$m	not reported	not reported	not reported	not reported	not reported	4.1	not reported	not reported	not reported	6.2	10.5	8.9
Total assets	$m	9.1	7.0	5.5	7.2	5.8	4.1	2.8	3.1	3.8	6.2	10.5	8.9
Current liabilities	$m	0.3	0.3	0.4	1.4	0.8	3.2	1.4	1.7	1.6	5.8	5.2	5.8
Total liabilities	$m	0.3	0.3	0.4	1.4	0.8	3.2	2.6	2.5	2.0	5.8	5.2	5.8
Shareholders' equity	$m	8.9	6.7	5.1	5.9	5.0	0.9	0.2	0.6	2.2	0.4	5.3	3.1

Cash flow

Operating cash flow−$1.9m, Q2 FY2026

Greenwich LifeSciences, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$k	(1,801)	(2,154)	(1,783)	(1,048)	(2,584)	(1,852)	(1,834)	(2,233)	(2,671)	(3,175)	(4,702)	(1,940)
Share repurchases	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)14.62m, Q2 FY2026

Greenwich LifeSciences, Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	12.8	12.8	12.8	12.8	12.9	12.9	13.1	13.2	13.4	13.6	14.6	14.6

Shares outstanding: 14.68m at Jul 24, 2026, from the cover of the 10-Q filed Aug 11, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. Listed shows no prices and gives no investment advice.